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Abstract
This retrospective, descriptive study aimed to assess hematologic testing practices in 100 patients with preeclampsia under-
going neuraxial blockade (NB). Prior to NB, platelet (PLT) c o u n tw a sp e r f o r m e di n6 1( 9 8 % )o f6 2w o m e ni nl a b o ra n di n3 7
(97%) of 38 women undergoing cesarean delivery (CD). No patients had a pre-NB PLT count <70   10
9/L. Pre-NB tests for
prothrombin time (PT) and activated partial thromboplastin time (APTT) were less common and varied among laboring
patients (15 [24%] of 62) and patients prior to CD (18 [47%] of 38). Prior to NB, PT and APTT values were within normal
limits in all patients. The time intervals between laboratory testing and NB ranged from <2 to >12 hours. The lack of consis-
tency in pre-NB coagulation testing and the variable time intervals between laboratory tests and NB may be due to a lack of
consensus among anesthesiologists for determining ‘‘safe’’ hemostatic conditions for NB placement in patients with
preeclampsia.
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Introduction
Laboratorytestsofplatelet(PLT)count,prothrombintime(PT),
and activated partial thromboplastin time (APTT) are relatively
common in patients with preeclampsia.
1-5 Although a low inci-
dence of severe thrombocytopenia and coagulopathy has been
reported in patients with mild and severe preeclampsia during
the peripartum period,
6-8 thrombocytopenia and coagulopathy
areimportantriskfactorsforthedevelopmentofepiduralhema-
toma following a neuraxial anesthetic technique, which include
single-shot spinal, epidural, or combined spinal–epidural
techniques.
9
The indications for laboratory testing of PLT, PT, and APTT
in all patients with preeclampsia undergoing neuraxial anesthe-
sia during the peripartum period are unclear. The most recent
American Society of Anesthesiologists (ASA) practice guide-
lines recommend obtaining PLT in patients with suspected
preeclampsia.
10 However, there are no recommendations for
timing preanesthesia laboratory tests prior to neuraxial block-
ade (NB) or on the indications for concomitant preanesthesia
coagulation testing in patients with preeclampsia. As a result,
these decisions are often at the discretion of the primary
anesthesiologist. Time delays may occur due to the perceived
need to request tests of PLT and coagulation function close
to the time of neuraxial block placement, which may unduly
affect patient care by subsequently delaying adequate labor
analgesia. Furthermore, anesthesiologists may be reluctant
to use a neuraxial anesthetic technique in a patient with
preeclampsia requiring urgent or nonelective cesarean delivery
without recent preoperative laboratory tests, which may culmi-
nate in the use of a general anesthetic and a higher potential risk
of patient comorbidity (cerebral hemorrhage following endo-
tracheal intubation).
11
To the best of our knowledge, no studies to date have
specifically investigated the timing of laboratory tests per-
f o r m e dp r i o rt od en o v oN Bi np r e e c l a m p t i cw o m e ni nt h e
peripartum period. The primary aim of this single-center,
retrospective study was to evaluate preanesthesia PLT and
coagulation indices in patients with preeclampsia who
receive de novo NB for labor analgesia or nonelective cesar-
ean delivery.
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After gaining institutional review board approval, we identified
a convenience sample of preeclamptic patients admitted to
Lucile Packard Children’s Hospital (LPCH) between January
2009 and August 2009. The LPCH is a university hospital and
tertiary obstetric center with >4000 deliveries per year. During
the study period, the labor and delivery unit at LPCH did not
have formal departmental guidelines for laboratory tests prior
to NB in patients with preeclampsia, and orders for laboratory
tests are requested by obstetricians or obstetric anesthesiolo-
gists on a case-by-case basis.
Patients
We searched an institutional electronic data warehouse using
administrative codes (specifically International Classification
of Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM]) for preeclampsia and hypertensive disease of pregnancy
to initially identify our patient cohort. Participants were identi-
fied using the following search criteria: mild or unspecified
preeclampsia (ICD-9-CM: 642.4), severe preeclampsia (ICD-
9-CM: 642.5), preeclampsia, or eclampsia superimposed on
preexisting hypertension (ICD-9-CM: 642.7). We subsequently
reviewed the medical records of patients identified from the
initial electronic search. Based on manual chart review, the
final study cohort was identified according to the following
inclusion criteria: patients with preeclampsia or HELLP syn-
drome (hemolysis, elevated liver enzymes and low platelet
count) undergoing either a trial of labor or nonelective cesarean
delivery receiving de novo NB (which includes an epidural,
single-shot spinal, or combined spinal–epidural technique). For
the purposes of this study, we did not define epidural anesthesia
using an epidural ‘‘top-up’’ for cesarean delivery in patients
with a preexisting epidural catheter as a de novo neuraxial
block. Exclusion criteria included patients with preeclampsia
undergoing elective (scheduled) cesarean delivery; intrauterine
fetal death; patients <18 years old; patients receiving anticoa-
gulant or antithrombotic drugs; patients with a previous history
of thrombocytopenia, history of acquired or inherited coagulo-
pathy, chronic hypertension, or nephropathy. Clinical and
laboratory data were abstracted from the medical records for all
patients included in the final study cohort.
Methods
During medical chart review, mild preeclamptic participants
were identified using current diagnostic criteria defined by the
American College of Obstetricians and Gynecologists
12-14: 2
systolic blood pressure (SBP) readings  140 mm Hg or diasto-
lic blood pressure (DBP) readings  90 mm Hg and  þ1 pro-
tein on urine dipstick evaluation or >300 mg protein excretion
in a 24-hour urinary sample. Severe preeclampsia was defined
according to the presence of 1 or more of the following criteria:
 2 SBP readings  160 mm Hg or DBP  110 mm Hg or evi-
dence of end organ damage ( 3 g proteinuria in 24 hours or
 þ3 protein on urine dipstick evaluation, central nervous sys-
tem, pulmonary or liver dysfunction, epigastric pain, or evi-
dence of fetal compromise). We also separately documented
laboratory and clinical data for patients with HELLP syn-
drome, based on the following diagnostic criteria
15,16:PLT <
150   10
9/L, aspartate transaminase >40 U/L, alanine transa-
minase >60 U/L (diagnosis of hemolysis by peripheral blood
smear or low serum haptoglobin if measured).
During medical record review, we recorded demographic,
obstetric data, and neuraxial anesthetic interventions. We
recorded the highest maternal SBP values, and data on protei-
nuria (24-hour urinary protein excretion, urinary protein dip-
stick evaluation within 1 week prior to delivery) to determine
the severity of preeclampsia during the peripartum period or
prior to nonelective cesarean delivery. Preneuraxial block
laboratory data abstracted were PLT, PT, and APTT. We also
recorded the lowest PLT and the highest PT, APTT, blood urea
nitrogen, creatinine levels measured between 48 hours before
deliveryto48hoursafterdelivery.Forthepurposesofthisstudy,
this time period was defined as ‘‘the peri-delivery period.’’
Laboratory PLT, PT, and APTT measurements are per-
formed in the Stanford University Medical Center Clinical
Laboratories. The PLT is measured using one of the following
instruments: Coulter LH 750 or LH 780 hematology analyzers
(Beckman Coulter, Inc, Brea, California); CELL-DYN Sap-
phire or CELL-DYN 1800 hematology analysers (Abbott
Laboratories, Abbott Park, Illinois). Both PT and APTT are
measured using the STA-R Evolution Expert Series Hemosta-
sis System (DiagnosticaStago, Inc, Parsippany, New Jersey).
Our primary outcome measures were to evaluate hematolo-
gic indices (PLT, PT, and APTT) in patients receiving de novo
NB for labor analgesia or de novo neuraxial anesthesia for
nonelective cesarean delivery. Secondary aims were to assess
the time intervals between laboratory testing and neuraxial
block placement and to examine potential relationships
between clinical/biochemical parameters and intrapartum
hematologic indices.
Statistical Analysis
Data are expressed as mean (SD), median (interquartile range),
and number or percentages as appropriate. Normal distribution
was determined using QQ plots and the Kolmogorov-Smirnov
test. Pearson and Spearman correlation coefficients were used
to assess the correlation between individual hematological
indices with biochemical parameters and clinical parameters
(highest SBP and DBP, 24-hour urinary protein levels) relevant
to preeclampsia. Microsoft Excel (Microsoft Corporation,
Redmond, Washington) wasused fordataentry, andIBM SPSS
Version19(IBMCorporation,Somers,NewYork)wasusedfor
data analyses; P < .05 was considered statistically significant.
Results
The initial electronic search identified 271 patients with ICD-9
codes for preeclampsia, and 100 patients met the inclusion
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graphic, obstetric, and delivery data are summarized in Table
1. In the study cohort, 75 patients underwent a trial of labor,
with most women (50 [67%] of 75) ultimately having a sponta-
neous or assisted vaginal delivery (Table 1). Neuraxial block-
ade was performed for labor analgesia in the majority of
patients undergoing a trial of labor (62 [83%] of 75; the remain-
der (13 [17%] of 75) did not receive neuraxial analgesia during
a trial of labor but ultimately received a neuraxial technique for
cesarean delivery. Fifty patients underwent cesarean delivery,
with an equal number of women (25 [50%] of 50) experiencing
and not experiencing labor (Table 1). For patients undergoing
cesarean delivery, 38 (76%) of 50 received a de novo neuraxial
anesthetic technique, 11 (22%) of 50 underwent epidural
anesthesia using the preexisting labor epidural (epidural
‘‘top-up’’) and 1 of 50 (2%) underwent general anesthesia. For
patients receiving labor analgesia and neuraxial anesthesia for
cesarean delivery, details of the de novo neuraxial techniques
performed and disease categories (mild preeclampsia, severe
preeclampsia, and HELLP syndrome) are presented in Table
2. The majority of patients undergoing NB for labor or nonelec-
tive cesarean delivery (>90%, respectively) were diagnosed
with mild or severe preeclampsia (Table 2).
Laboratory data for patients who received neuraxial labor
analgesia and patients who underwent neuraxial anesthesia
with a de novo technique for cesarean delivery are presented
in Table 3. The distribution of preblock platelet counts in all
patients, according to disease severity (mild preeclampsia,
severe preeclampsia, and HELLP syndrome), that received a
de novo neuraxial technique are presented in Figure 2. A pre-
anesthesia PLT was performed in the majority of women
(98%) receiving NB for labor analgesia, and in 97% women
undergoing neuraxial anesthesia for cesarean delivery. No
patients had a recorded PLT <70   10
9/L prior to neuraxial
block for labor analgesia or cesarean delivery (our departmen-
tal threshold for performing NB). One patient with HELLP
syndrome received a spinal anesthetic for cesarean delivery but
did not have a recorded preblock laboratory tests. This patient
experienced a massive postpartum hemorrhage requiring trans-
fusion of 9 units of packed red blood cells and 4 units of plate-
lets. The initial postoperative hematologic indices were PLT ¼
23   10
9/L; PT ¼ 15.8 seconds, and APTT ¼ 34.1 seconds.
The patient did not incur any neurological deficit or epidural
hematoma in the postpartum period.
Coagulation tests (PT and APTT), prior to NB for labor,
were performed in 24% women, and all patients had preblock
PT and APTT values within normal limits. Coagulation tests
were performed in nearly half of the women who underwent
de novo NB (47%) for cesarean delivery; PT and APTT values
were within normal limits for all patients.
The timing of the preanesthesia laboratory tests for NB for
labor and cesarean delivery is shown in Table 3. We observed
Table 1. Maternal Demographic and Obstetric Data.
a
N ¼ 100
Age, years 30 (8)
BMI, kg/m
2 34 (7)
b
Gestational age at delivery, weeks 36 (3)
Gravida 2 (1-3)
Parity 0 (0-1)
Singleton pregnancy 81 (81%)
Twin pregnancy 18 (18%)
Triplet pregnancy 1 (1%)
Ethnic group
Caucasian 26 (26%)
Hispanic 47 (47%)
Asian 16 (16%)
Pacific Islander 6 (6%)
African American 4 (4%)
Other 1 (1%)
Severity of preeclampsia
Mild preeclampsia 49 (49%)
Severe preeclampsia 45 (45%)
HELLP syndrome 6 (6%)
Modes of delivery
Spontaneous vaginal delivery 46 (46%)
Instrumental delivery 4 (4%)
Nonelective cesarean delivery 50 (50%)
c
Abbreviations: BMI, body mass index; SD, standard deviation.
a Data presented as n (%), mean (SD), and median (interquartile range).
b n ¼ 96 patients.
c Twenty-five women underwent nonelective cesarean delivery with labor; 25
women underwent nonelective cesarean delivery without labor.
Patients excluded ( n = 162)
> 1 entry for the same in-patient admission = 76
Pregnancy induced hypertension = 48
Not admitted as an in-patient = 11
<18 year old = 8
Not in labour = 7
Proteinuria without hypertension = 5
No hypertension or proteinuria = 4
Chronic hypertension = 1
Known renal disorder/ nephropathy = 1
Elective Cesarean section = 1
Patients identified from electronic search  
using ICD-9 codes for pre-eclampsia (n= 271)
Patients includedin final study cohort 
(n = 109)
Patients with mild pre-
eclampsia = 47 
Patients with severe pre-
eclampsia = 54
Patients with HELLP
syndrome = 8 
Figure 1. Flow diagram summarizing patient selection for the initial
and final study cohort.
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testing and placement of an NB, with preblock intervals vary-
ing from <2 to >12 hours.
We found no significant correlations between individual
clinical parameters (highest SBP, highest DBP, or 24-hour
urinary protein values) with individual hematological values
(lowest PLT, highest PT, or highest APTT; P > .05). However,
we observed significant negative correlations between the low-
est PLT and the highest APTT (r ¼  .25; P ¼.038) and highest
PT values (r ¼  .264; P ¼ .032) and between the highest
APTT and highest PT values (r ¼ .947; P < .001).
Discussion
In this retrospective study, severe thrombocytopenia (PLT <70
  10
9/L) was not detected in any of the patients with pree-
clampsia in this study cohort prior to NB. Nearly all patients
with preeclampsia receiving NB for labor analgesia (97%)o r
cesarean delivery (98%) had a PLT recorded prior to anesthe-
sia, which is in keeping with ASA guidelines. However, pre-
block coagulation testing in labor or cesarean delivery in
patients with preeclampsia undergoing NB occurred in fewer
patients and was more variable (incidence ¼ 24% and 47%,
respectively). Marked variability was also observed in the time
intervals between laboratory testing and neuraxial block place-
ment in all patients. The lack of consistency in performing coa-
gulation testing and the variability in the time intervals between
laboratory tests and NB may be related to subjective variability
among anesthesiologists for determining ‘‘safe’’ hemostatic
conditions for neuraxial block placement.
In our study, no patients with mild or severe preeclampsia
undergoing NB had clinically significant thrombocytopenia
(PLT <70   10
9/L) or prolonged PT or APTT values. These
results suggest that the patients with mild or severe disease
may have peripartum hematologic and coagulation indices
within an acceptable range for performing NB. Our results
are similar to those of Barker et al and Trotter et al who
reviewed predelivery PLT and laboratory coagulation tests
in patients with preeclampsia.
6,8 In the cohort of Barker of
over 400 patients with preeclampsia who underwent coagula-
tion testing prior to delivery, 90% had a PLT >100   10
9/L
and coagulation indices within a predefined normal range;
PLT <100   10
9/L occurred in 9% of all cases, all of whom
were diagnosed with severe preeclampsia.
6 Similarly, an
audit of 176 coagulation screens performed by Trotter et al
reported that no preeclamptic patients with PLT >150  
10
9/L were found to have abnormal coagulation.
8 However,
no specific details were provided in either study detailing the
timing of laboratory testing prior to NB.
No patients received NB with a preblock PLT <70   10
9/L,
which suggests that neuraxial anesthetic practice is in keeping
with our departmental guidelines or that anesthesiologists at
our institution have similar PLT thresholds when considering
NB. Although there is no consensus with regard to a PLT
threshold below which NB is contraindicated for patients with
preeclampsia, surveys of anesthesiologists’ preferences for per-
forming neuraxial block in nonpreeclamptic patients with
thrombocytopenia suggest the threshold above which neuraxial
block can be performed is between 50 and 100   10
9/L.
17,18,19
Our predetermined departmental PLT threshold of 70   10
9/L
for performing NB is within this range. Furthermore, guide-
lines from the American College of Obstetricians and Gynecol-
ogists state that healthy parturient with PLT between 50 and
100   10
9/L may be considered for regional anesthesia.
20
In our study, the presence of preblock coagulation studies
was less common than platelet counts. We speculate that
anesthesiologists order fewer tests of coagulation indices prior
Table 3. Hematologic Indices and Timing of Laboratory Results in
Patients Receiving Neuraxial Block for Labor Analgesia and Cesarean
Delivery.
a
Labor
Analgesia,
n ¼ 62
Cesarean
Delivery,
n ¼ 38
b
Preneuraxial block laboratory values
PLT ( 10
9/L) 206 (59) 200 (55)
APTT (seconds) 28.8 (2.6) 28.3 (27.0-28.7)
c
PT (seconds) 12.6 (0.8) 13.2 (12.6-13.5)
c
Hb 12.3 (1.4) 12.1 (1.6)
c
Timing of laboratory tests prior to neuraxial block
Not performed 1 (1.6%) 0
<2 hours 8 (12.9%) 5 (13.2%)
2-4 hours 13 (21.0%) 10 (26.3%)
4-6 hours 12 (19.4%) 9 (21.4%)
6-12 hours 15 (24.2%) 9 (21.4%)
>12 hours 13 (21.0%) 5 (11.9%)
Abbreviations: PT, prothrombin time; APTT, activated partial thromboplastin
time; Hb, hemoglobin; SD, standard deviation.
a Values presented as mean (SD), median (interquartile range), and n (%). PT:
normal reference range ¼ 11.4-14 seconds; APTT: normal reference range
¼ 25.1-34.7 seconds. Platelet count: normal reference range ¼ 150-400  
10
9/L.
b Excludes patients undergoing general anesthesia or epidural top-up technique
for cesarean delivery.
c n ¼ 37.
Table 2. Data on Severity of Preeclampsia and Anesthetic Technique
in Patients Undergoing De Novo Neuraxial Blockade for Labor
Analgesia and Cesarean Delivery.
a
Labor
Analgesia,
n ¼ 62
Cesarean
Delivery,
n ¼ 38
b
Severity of preeclampsia
Mild preeclampsia 38 (61%) 11 (29%)
Severe preeclampsia 22 (36%) 23 (61%)
HELLP syndrome 2 (3%) 4 (10%)
Neuraxial anesthetic technique
Combined spinal–epidural 10 (16.1%) 12 (22.2%)
Spinal 0 25 (46.3%)
Epidural 52 (83.9%) 1 (1.9%)
a Values presented as n (%).
b Excludes patients undergoing general anesthesia or epidural top-up technique
for cesarean delivery.
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clampsia. Our results are consistent with those of a previous
survey of obstetric anesthesia directors’ preferences for coagu-
lation testing in patients with preeclampsia.
21 In this survey,
variation in the need for preblock coagulation testing was
reported among respondents; 20% of anesthesiologists would
order coagulation tests for patients with mild preeclampsia and
75% of anesthesiologists would order these tests for patients
with severe preeclampsia.
21
One patient with HELLP syndrome received a spinal anes-
thetic for cesarean delivery without preanesthesia laboratory
tests and had prolonged PT (15.8 seconds) and profound throm-
bocytopenia (23   10
9/L), after receiving a massive transfu-
sion, in the postoperative period. In this case, the
preoperative hematologic and coagulation indices were
unknown. Rapidly decreasing PLT is a characteristic feature
of HELLP syndrome.
22,23 In addition, a previous study
reported a 30% incidence of coagulopathy in patients with
HELLP syndrome.
19 Although the incidence of spinal hema-
toma among the obstetric population is rare, a population-
wide study by Moen et al identified 2 obstetric patients, both
with HELLP syndrome, who developed spinal hematomas after
receiving NB.
24 Our case emphasizes the importance of close
hematological monitoring prior to neuraxial anesthesia in
patients with HELLP syndrome and the need to individualize
the decision to perform NB in patients with HELLP syndrome.
Inourstudy,therewasmarkedvariabilityinthetimeintervals
betweenlaboratorytestingand NB.Wespeculate thatthe lackof
consensus about the recommended time intervals for preblock
laboratorytestingandtheresultingvariationinanesthesiologists’
preferencesonourlaboranddeliveryunitcontributedtowardthe
markedvariabilityinthetimeintervalsbetweenlaboratorytesting
and neuraxial block placement. As a result, it is possible that
patientswithmildpreeclampsiamayexperiencedelaysinreceiv-
ing labor analgesia due to apprehension by the anesthesiologist
about proceeding with NB in the absence of a ‘‘normal’’ PLT
+ PT/APTT. However, preblock hematological laboratory test-
ing is justified in patients with severe preeclampsia and HELLP
syndrome due to the higher potential for hematological derange-
ment in these patient subpopulations.
We observed significant correlations between the lowest
PLT and the highest PT and APTT values. Previous work has
shown that an inverse relationship exists between platelet count
and antithrombin III activity
25 and that fibrinopeptide A con-
centrations are elevated in preeclampsia only when significant
activation of platelets occurs.
26 These results support a low
grade disseminated intravascular coagulation (DIC) picture in
the presence of severe preeclampsia, which may contribute to
an inverse relationship between lowest PLT and highest PT/
PTT values. However, our study was not powered to assess
individual relationships between biochemical indices, clinical
parameters, PLT, PT, and APTT in preeclamptics, and future
work is needed to formally assess these relationships.
Limitations of this study include the retrospective nature of
our study design. It is possible that we did not identify all
patients with preeclampsia in our initial search due to ICD-9
miscoding for preeclampsia. The inclusion of data on urinalysis
to determine proteinuria was incorporated into the inclusion
criteria as not all patients had 24-hour urine collection to con-
firm proteinuria of >300 mg/d or >3 g/d. Although 24-hour
urinary protein studies are known to be more accurate than uri-
nalysis in determining proteinurea in pregnancy,
27 we feel that
our data reflects clinical practice as clinical care often needs to
be delivered acutely for obstetric patients with preeclampsia
before 24-hour urinary protein results become available. Prea-
nesthesia coagulation tests were performed in 24% of laboring
patients and 47% of patients undergoing cesarean delivery
(undergoing a de novo anesthetic), therefore it is uncertain
whether coagulation abnormalities existed in patients with pre-
eclampsia within our study cohort, who did not receive prea-
nesthesia coagulation testing. We note that other studies have
reported variable incidences of thrombocytopenia (PLT <100
  10
9/L), prolonged PT, and prolonged APTT during preg-
nancy in patients with preeclampsia: 2% to 19%,
2,7,28 0% to
16%,
2,5 and 1.3% to 2.5%,
2,5 respectively. We were unable to
deduce whether anesthesiologists were primarily involved in
ordering laboratory tests prior to anesthetic intervention. As a
result, it is uncertain whether the requests for laboratory tests
were made by the obstetric or the anesthesia team, nor whether
the anesthesia team made specific requests regarding the timing
of laboratory testing prior to anesthetic intervention. Lastly,
these data are sourced from a single, obstetric tertiary-care cen-
ter with 24 hours in-house attending obstetric anesthesia cover-
age. Therefore, preblock hematological testing and obstetric/
anesthesia practices may vary at other academic and nonaca-
demic institutions.
In conclusion, we observed no evidence of clinically signif-
icant thrombocytopenia (<70   10
9/L) or coagulopathy in
patients with mild or severe preeclampsia who underwent
Figure 2. Median (interquartile range) in platelet counts for patients
with mild preeclampsia, patients with severe preeclampsia, and
patients with HELLP syndrome receiving de novo neuraxial blockade.
Horizontal line denotes median values, box borders refer to inter-
quartile range, whiskers indicate range of values, and circle indicates
outlier (>1.5 times the interquartile range).
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in the practice of preblock coagulation testing and in the time
intervals between laboratory testing and NB. Population-wide
studies incorporating comparative effectiveness research and
cost–benefit analyses
29 are needed to ascertain the indications,
timing, and relevance of laboratory testing prior to NB in
patients with preeclampsia.
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